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THE COLLECTING DUCT, LOCATED at the terminal part of the nephron, is responsible for reabsorption of Ͻ5% of sodiumfiltered load. However, this segment plays a key role in regulation of fluid and electrolyte balance in the body via final adjustment of urinary sodium excretion (3, 29, 37) . The mechanism of sodium reabsorption in the collecting duct requires coordination of sodium transport from the luminal side across apical membrane via a major carrier named epithelial sodium channel (ENaC). Sodium exits from the intracellular compartment to interstitial fluid via Na ϩ -K ϩ -ATPase located at basolateral membrane (12, 33, 35) . ENaC consists of three subunits including ␣, ␤, and ␥, in which ENaC␣ acts as a functional unit whereas ENaC␤ and ENaC␥ regulate the transport activity of the channel (7) . Overstimulation of the ENaC can lead to fluid retention and hence causes hypertension. This notion is based on the finding in Liddle syndrome where a mutation of the ␤-and/or ␥-subunits of ENaC produces an activated ion channel, resulting in severe sodium retention and hypertension (14, 30) .
Fine adjustment of sodium reabsorption mediated by ENaC is highly regulated by a key hormone aldosterone, which acts primarily through the mineralocorticoid receptor to alter the transcription of a set of target genes (9, 11, 18) . Aldosterone stimulates ENaC-mediated sodium reabsorption is mainly mediated by serum and glucocorticoid regulated kinase 1 (SGK1) that phosphorylates and inhibits ubiquitin-protein ligase Nedd4 -2, resulting in suppression of endocytosis and degradation of ENaC (22, 33, 34) . However, emerging evidence suggests that other factors such as corticosterone, insulin, and arginine vasopressin also modulate the function of this channel (16, 23, 24) .
Nuclear receptors play an important role in the regulation of cellular metabolic function such as lipid and glucose metabolism (4, 13) . Dysregulation of these processes causes development of metabolic diseases such as hyperlipidemia, diabetes, and cardiovascular disease (10, 17, 26, 28) . Liver X receptors (LXRs) belong to a family of nuclear receptors and are activated by the oxidized cholesterol derivatives, namely the natural ligands oxysterols, which form heterodimers with the retinoid X receptor (RXR) to regulate transcription of target genes governing cholesterol, fatty acid, and glucose metabolism (25, 28, 38) . LXRs consist of two isoforms including LXR␣ that is expressed in several tissues such as liver, small intestine, kidney, macrophages, and adipose tissue, whereas LXR␤ is more ubiquitously expressed (27) . LXRs have a crucial role in reverse cholesterol transport, thereby stimulating of cholesterol efflux from the peripheral tissue to the liver (10, 38) . LXRs have also been found to regulate the function of ATP-binding cassette (ABC) transporters such as ABCA1, ABCG1, ABCG5, and ABCG8 in macrophages and the small intestine (39) . In the kidney, LXR␣ expression is found in the glomeruli and glomerular mesangial cells and along the nephron segments (1, 20, 36, 40) . LXRs have been reported to regulate renal transporters such as Na-P i transporters (6) and organic anion transporter 1 (15) . Whether LXRs regulate ENaC expression or activity in the collecting duct is not known. The present study was undertaken to investigate the effect of LXR agonists on sodium transport mediated by ENaC in immortal cells (M1 cell) isolated from the murine cortical collecting duct as well as murine primary collecting duct cells. Our finding suggests that LXR agonists decreased renal ENaCmediated sodium reabsorption.
MATERIALS AND METHODS
Chemicals. T0901317 was obtained from Cayman Chemical (Ann Arbor, MI) whereas GW3965, 22 R-hydroxycholesterol, hyaluronidase, amiloride, and epidermal growth factor were purchased from Sigma (St. Louis, MO). Snapwell permeable supports were from Corning (Corning, NY). Collagen type I was obtained from Worthington Biochemical (Lakewood, NJ). All other chemicals used were of analytical grade and purchased from commercial sources.
Animals. Animal experiments were conducted in accordance with the Guidelines of the Laboratory Animal Ethical Committee of Mahidol University, Bangkok, Thailand, and animal procedures were approved by this committee. All mice were maintained in a temperature-controlled barrier facility with a 12:12-h light-dark cycle and were given free access to standard laboratory chow and tap water.
Cell culture. M1 cells were obtained from the American Type Culture Collection and grown in 37°C in humidified incubator gassed with 5% CO 2. Culture media consisted of DMEM/F-12 media supplemented with 5% FBS, 100 U/ml penicillin, and streptomycin, and 5 M dexamethasone. Primary cultures of renal collecting duct cells were generated with a modification of a previous study (32) . In brief, the renal medulla was isolated, minced, and digested for 60 min in digesting DMEM containing 0.2% collagenase type I, hyaluronidase, and 0.25% trypsin-EDTA at 37°C with shaking. After incubation, sterile distilled water was added for 20 min to lyse cells other than collecting duct cells by osmotic shock (100 mosmol/kgH 2O). Cells were then centrifuged at 1,000 rpm for 5 min, the supernatant was discarded, and the pellet was resuspended in the modified medium (DMEM; 10% FBS, 20 ng/ml and epidermal growth factor, and 100 U/ml penicillin G-streptomycin sulfate). Cells were seeded onto semipermeable membranes (12-mm diameter Snapwell) for electrophysiological studies. Media were replaced every 2 days.
Cell viability. The cell viability was determined using 3-(4,5-dimethyl-thiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. M1 cells were seeded on 96-well plates and then incubated with 10 M of T09013175 or 2 M GW3965 for 24 h. At the end of the incubation, cells were washed three times with PBS. MTT reagent was added to each well, and cells were incubated for another 4 h at 37°C. Then, MTT medium was removed and replaced with 150 l of 100% DMSO. Cell viability was examined by measuring the absorbance at 540 nm (EL 312 spectrophotometer, Bio-Kinetics Reader; Bio-Tek Instruments, Helsinki, Finland). Results are expressed as a percentage of the control value.
Electrophysiological transepithelial measurement. Only the cell monolayers that develop high resistance (M1 cells Ͼ 500 ⍀·cm 2 and primary inner medullary collecting duct cells Ͼ 1,000 ⍀·cm 2 ) were used for electrophysiological studies. Snapwell semipermeable membranes containing confluent cell monolayers were mounted in an Ussing chamber (Physiologic Instruments, San Diego, CA), and both surfaces of the cell monolayer were bathed in completed buffer (120 mM NaCl, 4.2 mM KCl, 34 mM NaHCO3, 0.3 mM MgCl2, 1 mM Na2HPO4, 0.4 mM MgSO4, 1.05 mM CaCl2, and 20 mM glucose) maintained at 37°C and equilibrated in 5% CO2-95% O2 to keep pH at 7.4. After a 60-min equilibration period, transepithelial potential difference (Vte) was measured using Ag-AgCl electrode in agar brides whereas short-circuit current (Isc) was recorded after the Vte was clamped at zero using a VCC600 voltage-clamp apparatus (Physiological Instruments). The ENaC-sensitive current was examined by adding 10 M amiloride at apical side.
RT-PCR. Total RNA was extracted from M1 cells using Trizol reagent (Invitrogen, CA) according the manufacturer's instructions. To make complementary DNA (cDNA), the mRNA was reverse transcribed with iScript select cDNA synthesis kit (Bio-Rad Laboratories, CA). PCR was carried out using Fast-Start Taq kit (Roche Diagnostics GmbH, Mannheim, Germany). The specific LXR␣ primers for mouse were forward: 5=-TCC ATC AAC CAC CCC CAC GAC-3= and reverse: 5=-CAG CCA GAA AAC ACC CAA CCT-3=, and for LXR␤: 5=-GCTCAGGAGCTGATGATCCA-3= and reverse: 5=-GCGCTTGATC-CTCGTGTAG-3=. PCR reactions were carried out for 30 cycles at 95°C for 30 s, at 62.5°C (LXR␣) or at 53°C (LXR␤) for 30 s, and then at 72°C for 1.0 min in a MJ Mini Personal Thermal Cycler (Bio-Rad Laboratories). PCR products were separated by electrophoresis in 2% agarose gels and visualized by staining with ethidium bromide.
Quantitative PCR. One microgram of total RNA was denatured at 65°C for 5 min, and cDNA synthesis was then performed at 42°C for 1 h using Superscript reverse transcriptase. Oligonucleotides were designed using Primer3 software (available at http://frodo.wi.mit. edu). Quantitative PCR amplification was performed using the SYBR Green Master Mix (Applied Biosystems) and the Prism 7500 RealTime PCR Detection System (Applied Biosystems). Cycling conditions were 95°C for 10 min, followed by 40 repeats of 95°C for 15 s and 60°C for 1 min.
Biotinylation. Cell-surface biotinylation was performed using the membrane-impermeable biotinylation reagents EZ-Link Sulfo-NHS-SS-Biotin (Pierce). M1 cells were incubated on ice with EZ-Link Sulfo-NHS-SS-Biotin for 30-min periods. After that, cells were rinsed with 3 ml of PBS/Ca 2ϩ /Mg 2ϩ containing 0.1 M glycine and then incubated on ice with the same solution for 20 min to ensure complete quenching of the unchanged EZ-Link Sulfo-NHS-SS-Biotin. The cells were harvested in lysis buffer containing 10 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100 with protease inhibitor cocktail for 1 h at 4°C. Samples were 4°C centrifuged at 1,2000 rpm for 20 min, and supernatants were incubated with 150 l streptavidin-agarose beads (Pierce) with overnight at 4°C with end-over-end mixing. Beads were then washed three times with lysis buffer and once with PBS. Proteins were released from the beads by incubation with buffer containing 100 mM dithiothreitol for 30 min at 50°C.
Western blot analysis. Equal amounts (50 g) of protein from the lysate were separated by 10% SDS-PAGE and transferred to a Hybond-ECL nitrocellulose membrane (Amersham Biosciences). The membrane was incubated for 1 h in 5% nonfat dry milk and then blotted with rabbit polyclonal antibodies against SERBP-1c, ENaC␤, ENaC␥, Na ϩ -K ϩ -ATPase ␣, or mouse monoclonal antibodies against ␤-actin at 4°C overnight. After incubation with the primary antibody, the membrane was washed three times for 15 min each and incubated for 1 h with a 1:2,000 dilution of secondary antibody at room temperature. After the membrane was washed three times, immunoreactivity was detected by chemiluminescence and visualized by using enhanced chemiluminescence Western blot reagents and hyperfilm ECL (Amersham Biosciences).
Data analysis. Data are summarized as means Ϯ SE. Statistical analysis was performed using one-way ANOVA.
RESULTS

Expression of LXR␣ and LXR␤ in M1 cells.
To verify whether the cell system used in our study expresses LXR␣ and LXR␤, the expressions of LXRs mRNA in M1 cells were examined using RT-PCR. We found that both LXR␣ and LXR␤ isoforms were expressed in M1 cells (Fig. 1A) . LXR activations in M1 cells following treatment with the LXR agonists T0901317 and GW3965 were confirmed by detection of SREBP-1c protein, a product of LXR target gene. Western blots revealed that T0901317 and GW3965 increased the expression of SREBP-1c protein (Fig. 1B) .
Effect of LXR agonists on amiloride-sensitive I sc in M1 cells. We examined the dose-response of LXR agonists on ENaCmediated sodium transport in M1 cells by measurement of amiloride-sensitive I sc . Confluent cell monolayers were preincubated with several concentrations of LXR agonists (T0901317 and GW3965) for 24 h. The monolayer was mounted in Ussing chamber for a 60-min equilibration period, followed by measurement of the amiloride-sensitive I sc in the presence of 10 M amiloride added to the apical side of the chamber. As shown in Fig. 2A , exposure the cells to synthetic LXR agonists (T0901317 or GW3965) led to a dose-dependent decrease in I sc that was detectable at 5 M for T0901317 and 2 M for GW3965. Based on these findings, 10 M T0901317 and 2 M GW3965 were selected as the concentrations for subsequent experiments. We also determined the effect of the natural ligand of LXR 22R-hydroxycholesterol on ENaC-mediated sodium transport. The monolayer was incubated with 20 M of 22R-hydroxycholesterol for 24 h followed by measurement of amiloride-sensitive I sc . As expected, 22R-hydroxycholesterol decreased amiloride-sensitive I sc by 30% compared with vehicle treatment (Fig. 2B) . To determine the optimal time required for LXR agonist to exhibit its action, the M1 cells were incubated with T0901317 for different time periods followed by measurement of amiloride-sensitive I sc . The inhibition of T0901317 was observed after 24 h, and there was a trend to further inhibition after 48 h incubation (Fig. 2C) . We further determined whether the reduction of sodium transport was associated by cytotoxicity using two different parameters including transepithelial resistance (TER) and MTT assay. As shown in Fig. 3 , 10 M T0901317 and 2 M GW3965 increased TER compared with vehicle. MTT assay demonstrated comparable cell viability among different groups.
Effect of LXR agonists on Na ϩ -K ϩ -ATPase in M1 cell. Transepithelial transport of sodium is reflected by both apical and basolateral transport that was mediated by ENaC and Na ϩ -K ϩ -ATPase, respectively. Therefore, we determined whether dose-dependent effect of T0901317 and GW3965; the cell monolayers were preincubated with serum-free medium containing several concentration of T0901317 or GW3965 for 24 h and then the Am-sensitive Isc was measured by addition of 10 M amiloride at the apical side (n ϭ 9 monolayers). B: effect of natural ligand of LXRs (22R-HC) on Am-sensitive Isc (n ϭ 7-9 monolayers). C: time-dependent effect of 10 M T0901317 at several time intervals followed by Am-sensitive Isc measurement (n ϭ 6 monolayers). Data are expressed as means Ϯ SE. *P Ͻ 0.05, significantly different from control.
the LXR agonists affect Na ϩ -K ϩ -ATPase activity. The Na ϩ / K ϩ -ATPase activity was determined by apical permeabilization (250 g/ml amphotericin B), which allowed ions freely transport from lumen into the cell. After the I sc became stable, 1 mM ouabain was added to the basolateral side to measure the transport activity of the Na ϩ -K ϩ -ATPase. As shown in Fig.  4A , the exposure of the cell monolayer to 10 M T0901317 or 2 M GW3965 had no effect on ouabain-sensitive I sc compared with the control value. Consistent with this result, neither T0901317 nor GW5965 treatment exhibited a significant effect on mRNA or protein expression of Na ϩ -K ϩ -ATPase ␣ subunit (Fig. 4, B and C) .
Treatment of M1 cells with LXR agonists decreased ENaC mRNA and protein expression in M1 cells. Next, we determined the effect of T0901317 and GW3965 on mRNA expression of ENaC subunits including ␣, ␤, and ␥ in M1 cells. The M1 cells were preincubated with 10 M T0901317 or 2 M GW3965 for 24 h followed by measurement of mRNA expression. Incubation with T0901317 or GW3965 produced a significant reduction of mRNA expression in all subunits of ENaC compared with vehicle treatment (Fig. 5A) . We further measured protein expression of ENaC␤ and ENaC␥ in the cells after incubation with 10 M T0901317 or 2 M GW3965 for 24 h. As shown in Fig. 5 , B and C, T0901317 and GW3965 significantly decreased both total and membrane protein expression of ENaC␤ and ENaC␥ compared with vehicle group.
Effect of LXR agonist of aldosterone-induced stimulation of ENaC-mediated sodium transport in M1 cells.
Since ENaCmediated sodium transport was chiefly regulated by aldosterone, we investigated whether LXR agonist modulated the action of aldosterone in M1 cells. The cell monolayer was incubated in four conditions: 1) vehicle control, 2) 2 M GW3965 for 24 h, 3) 1 M aldosterone for 24 h, and 4) 2 M GW3965 for 4 h followed by aldosterone plus GW3965 for further 24 h. At the end of incubation period, the monolayers were mounted in an Ussing chamber for measurement of amiloride-sensitive I sc . As shown in Fig. 6 , aldosterone stimulated amiloride-sensitive I sc in vehicle-treated cells whereas the stimulatory effect of aldosterone was not observed in GW3965-treated cells.
Effect of LXR agonists on amiloride-sensitive I sc in primary culture of collecting duct cells. We investigated the effect of T0901317 and GW3965 on ENaC-mediated sodium transport in primary collecting duct cells. Incubation of the cell monolayers in medium containing 10 M T0901317 or 2 M GW3965 for 24 h caused decrease in amiloride-sensitive I sc (Fig. 7A) . The TER of the monolayer after treated with T0901317 or GW3965 was slightly increased, but this change did not reach a statistical significance (Fig. 7B) . Fig. 3 . Effect of LXR agonists on transepithelial resistance (TER) and cell viability in M1 cells. M1 cells were incubated with 10 M T0901317 or 2 M GW3965 for 24 h. At the end of incubation, TER of cell monolayer was measured. Numbers in bars indicate the number of monolayers (A) whereas the cell viability was measured using 3-(4,5-dimethyl-thiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (B). Data are shown as means Ϯ SE from at least 3 separate experiments for MTT assay. *P Ͻ 0.05, compared with vehicle group. Fig. 4 . Effect of T0901317 and GW3965 on Na ϩ /K ϩ -ATPase in M1 cell monolayers. M1 cell monolayers were treated with vehicle or 10 M T0901317 or 2 M GW3965 for 24 h followed by measurement of Na ϩ /K ϩ -ATPase activity (A; numbers indicated in bars represent cell monolayers), Na ϩ -K ϩ -ATPase ␣ mRNA expression (B), and protein expression of Na ϩ /K ϩ -ATPase ␣ (C). Data are shown as means Ϯ SE from 3 independent experiments for B and C. NS is no significant difference compared with control.
DISCUSSION
ENaC plays a crucial role in body electrolytes and water homeostasis. Upregulation of the channel leads to fluid retention and subsequently causes hypertension development as found in Liddle's syndrome whereas downregulation of the channel causes wasting of body fluid (5, 30) . The intervention that reduces accumulation of sodium in the body is appreciable for treatment of fluid retention-associated diseases such as hypertension. The classical intervention for treatment of hypertension has been established using ENaC blockers such as the diuretic drug amiloride (7, 31) . In this study, we showed that LXR agonists including both synthetic ligands (T0901317 and GW3965) and natural ligand (oxysterol) decreased sodium transport mediated by ENaC in collecting duct cells, M1 cells, that endogenously expresses LXR␣ and LXR␤. Although a high concentration of T0901317 could activate pregnane X receptor (PXR) and farnesoid X receptor (FXR; Ref. 19) , its inhibitory effect was not mediated by PXR and FXR activation. In support of this notion, GW3965 that had no effect on PXR and FXR activation (19) produced a similar effect as that found in T0901317 treatment. The consistent results obtained with structurally distinct LXR ligands strongly suggest a specific effect of LXR on ENaC-mediated sodium transport. However, these ligands are limited in that they nonselectively actively both LXR␣ and LXR␤ (2, 27) . Future studies are needed to take a molecular approach or use more selective agonists/antagonists to define the role of a particular LXR subtype.
The most novel finding of the present study is the demonstration that LXR activation inhibits ENaC-mediated sodium transport in the collecting duct cells. The Ussing chamber technique demonstrated an inhibitory effect of LXR agonists on amiloride-sensitive I sc . This phenomenon was noticed after 24 h of drug treatment, indicating a slow mode of action of LXR. ENaC expression analysis consistently demonstrated both T0901317 and GW3965 reduced all three ENaC subunits by almost 50%. The downregulation of ENaC␤ and ENaC␥ was further validated at the protein level in both total protein and membrane expression; ENaC␣ protein was not examined because the anti-ENaC␣ antibody did not perform well. It is most likely that inhibition of ENaC expression accounts for the inhibitory effect of LXR activation on amiloride-sensitive sodium transport. The inhibition of ENaC expression may primarily occur at the transcript level. However, the precise mechanism how LXR activation inhibits ENaC mRNA expression is unknown. A previous study reported that LXRs repressed glucocorticoid receptor-stimulated transactivation of glucocorticoid response element-driven promoters in a genespecific fashion (21) . Therefore, it is possible that LXRs may directly suppress promoter activity of ENaC. This hypothesis needs to be further verified. An issue arises that the immortalization procedure for generating the M1 cell line may artificially affect the transport property of the cells. We subsequently validated the effect of LXR agonists in primary cultures of collecting duct cells. Future studies are needed to test the potential role of LXR in the regulation of electrolytes and body fluid homeostasis animal models in vivo.
The transcellular transport of sodium is mediated by transport of sodium across apical membrane and basolateral transport from the cell to interstitial fluid. The inhibitory effect of LXR agonists on sodium transport can be the result of a decrease in either apical ENaC-mediated transport function or basolateral Na ϩ -K ϩ -ATPase transport function (12, 33, 35) . We found that LXR agonists had no effect on Na ϩ -K ϩ -ATPase activity as reflected by ouabain-sensitive I sc . In addition, mRNA and protein expression of Na ϩ -K ϩ -ATPase ␣ were not affected by LXR-activating ligands in this cell model. These results have ruled out the involvement of Na ϩ -K ϩ -ATPase. In support of this notion, the LXR agonist (GW3965) did not inhibit Na ϩ -K ϩ -ATPase activity but restored the reduction in Na ϩ -K ϩ -ATPase activity in neural cells induced by diabetes (8) .
ENaC-mediated sodium transport in collecting duct is tightly regulated by aldosterone that increases sodium reabsorption in the collecting duct (22, 33, 34) . We examined the effect of LXR activation on aldosterone-induced ENaC activity. In this experiment, GW3965 significantly reduced the baseline ENaC activity and almost abolished the stimulatory effect of aldosterone. These results suggest that LXR may serve as an important negative regulator of aldosterone-induced ENaC activity in the distal nephron. Since LXR is a well-characterized sensor of cholesterone and glucose, it seems reasonable to speculate that LXR may play a physiological role in linking energy metabolism and sodium balance via modulating the action of aldosterone.
In summary, we have demonstrated for the first time that LXR activation exerts an inhibitory effect on ENaC-mediated sodium transport in the collecting duct cells. This inhibition was likely due to the reduction of expression of all three ENaC subunits. We speculate that LXR may function as a physiological link between cellular energy metabolism and ENaC transport function. In addition, LXR agonists may have the potential to develop into an antihypertensive agent due to their natriuretic and diuretic property.
